Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00368251 · ClinicalTrials.gov registry record · Phase 3
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 56
- Enrollment target
NCT00368251 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 56 participants.
The verdict
NCT00368251, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 56 participants
- Enrollment target
Study Summary
The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
Interventions
- OTHER Placebo
- DRUG BRV 2.5 mg
- DRUG BRV 25 mg
- DRUG BRV 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00368251
The ClinicalTrials.gov registry entry for NCT00368251 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00368251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00368251 about?
NCT00368251 is a clinical study titled "Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults". The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).
What is the current status of trial NCT00368251?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 56 participants. The study started on 2006-11. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00368251?
The interventions under investigation include: Placebo (OTHER), BRV 2.5 mg (DRUG), BRV 25 mg (DRUG), BRV 50 mg (DRUG).
Who is sponsoring clinical trial NCT00368251?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.